Bausch Health Companies (BHC) Stock Price, News & Analysis

Company Overview

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

Key Stats

• Today's Range: C$8.36 to C$8.62
• 50-Day Range: C$7.88 to C$9.65
• 52-Week Range: C$6.10 to C$11.08
• Volume: 253,091 shs
• Average Volume: 539,998 shs
• Market Capitalization: C$3.16 billion
• P/E Ratio: N/A
• Dividend Yield: 0.76%
• Price Target: N/A
• Consensus Rating: Hold

Bausch Health Companies Stock Analysis - MarketRank™

Bausch Health Companies scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Bausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bausch Health Companies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch Health Companies is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch Health Companies is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Bausch Health Companies has a PEG Ratio of 0.21. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BHC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Bausch Health Companies has a dividend yield of 0.76%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bausch Health Companies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.22

News Sentiment

Bausch Health Companies has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bausch Health Companies this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for BHC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bausch Health Companies insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.28% of the stock of Bausch Health Companies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.50% of the stock of Bausch Health Companies is held by institutions.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/14/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: TSE:BHC
• CIK: N/A
• Web: www.bauschhealth.com
• Phone: 514-744-6792
• Fax: N/A
• Employees: 20,300
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($2.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 1.52
• P/E Growth: 0.21
• Net Income: -C$125.65 million
• Net Margins: -12.02%
• Pretax Margin: N/A
• Return on Equity: 87.57%
• Return on Assets: 4.16%

Debt

• Debt-to-Equity Ratio: -1,173.29
• Current Ratio: 1.44
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: C$10.85 billion
• Price / Sales: 0.29
• Cash Flow: C$1.09 per share
• Price / Cash Flow: 7.76
• Book Value: C($2.14) per share
• Price / Book: -3.95

Miscellaneous

• Outstanding Shares: 373,991,000
• Free Float: N/A
• Market Cap: C$3.16 billion
• Optionable: Not Optionable
• Beta: 0.82